{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:50:59Z","timestamp":1794376259121,"version":"4.9.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1038\/s41440-025-02175-2","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T04:15:36Z","timestamp":1742876136000},"page":"1929-1938","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Real-world use of finerenone in patients with chronic kidney disease and type 2 diabetes based on large-scale clinical studies: FIDELIO-DKD and FIGARO-DKD"],"prefix":"10.1038","volume":"48","author":[{"given":"Atsuhisa","family":"Sato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Nishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"2175_CR1","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.3390\/ijms18051032","volume":"18","author":"JW Funder","year":"2017","unstructured":"Funder JW. Aldosterone and mineralocorticoid receptors \u2013 Physiology and pathophysiology. Int J Mol Sci. 2017;18:1032. https:\/\/doi.org\/10.3390\/ijms18051032.","journal-title":"Int J Mol Sci"},{"key":"2175_CR2","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1210\/en.2010-1444","volume":"152","author":"KS Kassahn","year":"2011","unstructured":"Kassahn KS, Ragan MA, Funder JW. Mineralocorticoid receptors: evolutionary and pathphysiological consideration. Endocrinology. 2011;152:1883\u201390.","journal-title":"Endocrinology"},{"key":"2175_CR3","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0039-128X(96)00020-7","volume":"61","author":"MJ Young","year":"1996","unstructured":"Young MJ, Funder JW. Mineralocorticoids, salt, hypertension: effects on the heart. Steroids. 1996;61:233\u20135.","journal-title":"Steroids"},{"key":"2175_CR4","first-page":"247","volume":"52","author":"JW Funder","year":"1997","unstructured":"Funder JW, Krozowski Z, Myles K, Sato A, Sheppard KE, Young M. Mineralocorticoid receptors, salt, and hypertension. Recent Prog Horm Res. 1997;52:247\u201360.","journal-title":"Recent Prog Horm Res"},{"key":"2175_CR5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00045415-200203000-00008","volume":"10","author":"CT Stier Jr","year":"2002","unstructured":"Stier CT Jr, Chander PN, Rocha R. Aldosterone as a mediator in cardiovascular injury. Cardiol Rev. 2002;10:97\u2013107.","journal-title":"Cardiol Rev"},{"key":"2175_CR6","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/HYPERTENSIONAHA.123.21369","volume":"81","author":"M Nishimoto","year":"2024","unstructured":"Nishimoto M, Griffin K, Wynne BM, Fujita T. Salt-sensitive hypertension and the kidney. Hypertension. 2024;81:1206\u201317.","journal-title":"Hypertension"},{"key":"2175_CR7","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/s41440-022-00940-1","volume":"45","author":"A Sato","year":"2022","unstructured":"Sato A, Nishimoto M. Clinical effect of nonsteroidal mineralocorticoid receptor (MR) antagonists in the treatment of diabetic kidney disease: expectations as a new therapeutic strategy. Hypertens Res. 2022;45:1310\u201321.","journal-title":"Hypertens Res"},{"key":"2175_CR8","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1210\/en.2006-0944","volume":"147","author":"C Guo","year":"2006","unstructured":"Guo C, Martinez-Vasquez D, Mendez GP, Toniolo MF, Yao TM, Oestreicher EM, et al. Mineralocorticoid receptor antagonist reduces renal injury in rodent models of type 1 and 2 diabetes mellitus. Endocrinology. 2006;147:5363\u201373.","journal-title":"Endocrinology"},{"key":"2175_CR9","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ejphar.2008.06.019","volume":"589","author":"M Taira","year":"2008","unstructured":"Taira M, Toba H, Murakami M, Iga I, Serizawa R, Murata S, et al. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats. Eur J Pharmacol. 2008;589:264\u201371.","journal-title":"Eur J Pharmacol"},{"key":"2175_CR10","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1210\/endo.137.10.8828470","volume":"137","author":"A Sato","year":"1996","unstructured":"Sato A, Funder JW. High glucose stimulates aldosterone-induced hypertrophy via type I mineralocorticoid receptors in neonatal rat cardiomyocytes. Endocrinology. 1996;137:4145\u201353.","journal-title":"Endocrinology"},{"key":"2175_CR11","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0895-7061(03)00913-0","volume":"16","author":"A Sato","year":"2003","unstructured":"Sato A, Saruta T. Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy. Am J Hypertens. 2003;16:781\u20138.","journal-title":"Am J Hypertens"},{"key":"2175_CR12","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","volume":"41","author":"A Sato","year":"2003","unstructured":"Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension. 2003;41:64\u20138.","journal-title":"Hypertension"},{"key":"2175_CR13","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1161\/01.HYP.0000022606.52221.2F","volume":"40","author":"M Naruse","year":"2002","unstructured":"Naruse M, Tanabe A, Sato A, Takagi S, Tsuchiya K, Imaki T, et al. Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension. 2002;40:28\u201333.","journal-title":"Hypertension"},{"key":"2175_CR14","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1291\/hypres.29.211","volume":"29","author":"A Sato","year":"2006","unstructured":"Sato A, Saruta T, Funder JW. Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection. Hypertens. Res. 2006;29:211\u20136.","journal-title":"Hypertens. Res."},{"key":"2175_CR15","doi-asserted-by":"crossref","unstructured":"Ando K, Ohtsu H, Uchida S, Kaname S, Arakawa Y, Fujita T, for the EVALUATE Study Group Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomized, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2:944\u201353.","DOI":"10.1016\/S2213-8587(14)70194-9"},{"key":"2175_CR16","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/s41440-018-0201-7","volume":"42","author":"M Nishimoto","year":"2019","unstructured":"Nishimoto M, Ohtsu H, Marumo T, Kawarazaki W, Ayuzawa N, Ueda K, et al. Mineralocorticoid receptor blockade suppresses dietary salt-induced ACEI\/ARB-resistant albuminuria in non diabetic hypertension: a sub-analysis of evaluate study. Hypertens Res. 2019;42:514\u201321.","journal-title":"Hypertens Res"},{"key":"2175_CR17","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/hr.2012.182","volume":"36","author":"A Sato","year":"2013","unstructured":"Sato A. Mineralocorticoid receptor antagonists: their use and differentiation in Japan. Hypertens Res. 2013;36:185\u201390.","journal-title":"Hypertens Res"},{"key":"2175_CR18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","volume":"64","author":"P Kolkhof","year":"2014","unstructured":"Kolkhof P, Delbeck M, Kretschmer A, Steinke W, Hartmann E, B\u00e4rfacker L, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol. 2014;64:69\u201378.","journal-title":"J Cardiovasc Pharmacol"},{"key":"2175_CR19","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/cmdc.201200081","volume":"7","author":"L B\u00e4rfacker","year":"2012","unstructured":"B\u00e4rfacker L, Kuhl A, Hillisch A, Grosser R, Figueroa-Perez S, Heckroth H, et al. Discovery of BAY 94-8862: A nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem. 2012;7:1385\u2013403.","journal-title":"ChemMedChem"},{"key":"2175_CR20","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","volume":"34","author":"B Pitt","year":"2013","unstructured":"Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failureand mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34:2453\u201363.","journal-title":"Eur Heart J"},{"key":"2175_CR21","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. for the FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219\u201329.","journal-title":"N Engl J Med"},{"key":"2175_CR22","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris G, Rossing P, et al. for the FIGARO-DKD Investigators. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385:2252\u201363.","journal-title":"N Engl J Med"},{"key":"2175_CR23","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. FIDELIO-DKD and FIGARO-DKD investigators. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43:474\u201384.","journal-title":"Eur Heart J"},{"key":"2175_CR24","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.3390\/jcm13175107","volume":"13","author":"A Sato","year":"2024","unstructured":"Sato A, Rodriguez-Molina D, Yoshikawa-Ryan K, Yamashita S, Okami S, Liu F, et al. Early clinical experience of finerenone in people with chronic kidney disease and type 2 diabetes in Japan \u2013 A multi-cohort study from the FOUNTAIN (FinerenOne mUltidatabase NeTwork for Evidence generAtIoN) platform. J Clin Med. 2024;13:5107. https:\/\/doi.org\/10.3390\/jcm13175107.","journal-title":"J Clin Med"},{"key":"2175_CR25","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, et al. for the Mineralocorticoid Receptor Antagonist Tolerability Study-Diabetic Nephropathy (ARTS-DN) Study Group. Effect of finerenone on albuminuria in patients with diabetic nephropathy. A randomized clinical trial. JAMA. 2015;314:884\u201394.","journal-title":"JAMA"},{"key":"2175_CR26","doi-asserted-by":"crossref","unstructured":"Katayama S, Yamada D, Nakayama M, Yamada T, Myoishi M, Kato M, ARTS-DN Japan Study Group et al. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diab etic nephropathy. J Diabetes complications. 2017;31:758\u201365.","DOI":"10.1016\/j.jdiacomp.2016.11.021"},{"key":"2175_CR27","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/ckj\/sfac234","volume":"16","author":"R Agarwal","year":"2023","unstructured":"Agarwal R, Pitt B, Palmer BF, Kovesdy CP, Burgess E, Filippatos G, et al. A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease. Clin Kidney J. 2023;16:293\u2013302.","journal-title":"Clin Kidney J"},{"key":"2175_CR28","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","volume":"394","author":"R Agarwal","year":"2019","unstructured":"Agarwal R, Rossignol P, Romero A, Garza D, Mayo MR, Warren S, et al. Patiromer versus placebo to enable spironolactone use in patients with re sistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2019;394:1540\u201350.","journal-title":"Lancet"},{"key":"2175_CR29","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2021070942","volume":"33","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Joseph A, Anker SD, Filippatos G, Rossing P, Ruilope LM, et al. on behalf of the FIDELIO-DKD Investigators. Hyperkalemia risk with finerenone: Results from the FIDELIO-DKD trial. J Am Soc Nephrol. 2022;33:225\u201337.","journal-title":"J Am Soc Nephrol"},{"key":"2175_CR30","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.semnephrol.2014.04.008","volume":"34","author":"I Lazich","year":"2014","unstructured":"Lazich I, Bakris GL. Prediction and management of hyperkalemia across the spectrum of chronic kidney disease. Semin Nephrol. 2014;34:333\u20139.","journal-title":"Semin Nephrol"},{"key":"2175_CR31","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/archinternmed.2009.132","volume":"169","author":"LM Einhorn","year":"2009","unstructured":"Einhorn LM, Zhan M, Hsu VD, Walker LD, Moen MF, Seliger SL, et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Int Med. 2009;169:1156\u201362.","journal-title":"Arch Int Med"},{"key":"2175_CR32","doi-asserted-by":"publisher","first-page":"e005428","DOI":"10.1161\/JAMA.116.005428","volume":"19","author":"G Bandak","year":"2017","unstructured":"Bandak G, Sang Y, Gasparini A, Chang AR, Ballew SH, Evans M. et al. Hyperkalemia after initiating renin-angiotensin system blockade: The Stockholm Creatinine Measurement (SCREAM) Project. J Am Heart Assoc. 2017;19:e005428. https:\/\/doi.org\/10.1161\/JAMA.116.005428.","journal-title":"J Am Heart Assoc"},{"key":"2175_CR33","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jchf.2022.07.013","volume":"10","author":"G Filippatos","year":"2022","unstructured":"Filippatos G, Anker SD, Pitt B, Rossing P, Joseph A, Kolkhof P, et al. Finerenone and heart failure outcomes by kidney function\/albuminuria in chronic kidney disease and diabetes. JACC Heart Failure. 2022;10:860\u201370.","journal-title":"JACC Heart Failure"},{"key":"2175_CR34","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.kint.2022.08.040","volume":"103","author":"GL Bakris","year":"2023","unstructured":"Bakris GL, Ruilope L, Anker SD, Filippatos G, Pitt B, Rossing P, et al. on behalf of the FIDELIO-DKD and FIGARO-DKD Investigators. A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes. Kidney Int. 2023;103:196\u2013206.","journal-title":"Kidney Int"},{"key":"2175_CR35","doi-asserted-by":"crossref","first-page":"602","DOI":"10.2215\/CJN.0000000000000149","volume":"18","author":"P Sarafidis","year":"2023","unstructured":"Sarafidis P, Agarwal R, Pitt B, Wanner C, Filippatos G, Boletis J, et al. on behalf of the FIDELIO-DKD and FIGARO-DKD Investigators. Outcomes with finerenone in participants with stage 4 CKD and type 2 diabetes. A FIDELITY subgroup analysis. Clin J Am Soc Nephrol. 2023;18:602\u201312.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2175_CR36","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. for the CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 201 9;380:2295\u2013306.","journal-title":"N Engl J Med"},{"key":"2175_CR37","first-page":"1436","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. for the DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436\u201346.","journal-title":"for the DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med"},{"key":"2175_CR38","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"The EMPA-KIDNEY Collaborative Group.","year":"2023","unstructured":"The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388:117\u201327.","journal-title":"N Engl J Med"},{"key":"2175_CR39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ckj\/sfad249","volume":"17","author":"FH Marup","year":"2024","unstructured":"Marup FH, Thomsen MB, Birn H. Additive effects of dapagliflozin and finerenone on albuminuria in non-diabetic CKD: an open-label randomized clinical trial. Clin Kidney J. 2024;17:1\u20139.","journal-title":"Clin Kidney J"},{"key":"2175_CR40","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","volume":"149","author":"BL Neuen","year":"2024","unstructured":"Neuen BL, Heerspink HJL, Vart P, Claggett BL, Fletcher RA, Arnott C, et al. Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria. Circulation. 2024;149:450\u201362.","journal-title":"Circulation"},{"key":"2175_CR41","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1159\/000516213","volume":"52","author":"P Kolkhof","year":"2021","unstructured":"Kolkhof P, Hartmann E, Freyberger A, Pavkovic M, Mathar I, Sandner P, et al. Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage. Am J Nephrol. 2021;52:642\u201352.","journal-title":"Am J Nephrol"},{"key":"2175_CR42","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/ndt\/gfac198","volume":"38","author":"JB Green","year":"2023","unstructured":"Green JB, Mottl AK, Bakris G, Heerspink HJL, Mann JFE, McGill JB, et al. Design of the combination effect of finerenone and empagliflozin in participants with chronic kidney disease and type 2 diabetes using a UACR endpoint study (CONFIDENCE). Nephrol Dial Transplant. 2023;38:894\u2013903.","journal-title":"Nephrol Dial Transplant"},{"key":"2175_CR43","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jacc.2021.01.044","volume":"77","author":"JP Ferreira","year":"2021","unstructured":"Ferreira JP, Zannad F, Pocock SJ, Anker SD, Butler J, Filippatos G, et al. Interplay of mineralocorticoid receptor antagonists and empagliflozin in heart failure: EMPEROR-Reduced. J Am Coll Cardiol. 2021;77:1397\u2013407.","journal-title":"J Am Coll Cardiol"},{"key":"2175_CR44","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.2215\/CJN.0000000000000205","volume":"18","author":"L Xiaoling","year":"2023","unstructured":"Xiaoling L, Jing X, Shoulian Z, Cheng X, Zewei C, Zhiguo M. Influence of SGLT2i and RAASi and their combination of risk of hyperkalemia in DKD. A network meta-analysis. Clin J Am Soc Nephrol. 2023;18:1019\u201330.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2175_CR45","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.dsx.2017.08.003","volume":"12","author":"TD Filippatos","year":"2018","unstructured":"Filippatos TD, Tsimihodimos V, Liamis G, Elisaf MS. SGLT2 inhibitors-induced electrolyte abnormalities: An analysis of the associated mechanisms. Diabetes Metab Syndr. 2018;12:59\u201363.","journal-title":"Diabetes Metab Syndr"},{"key":"2175_CR46","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ekir.2021.10.008","volume":"7","author":"P Rossing","year":"2022","unstructured":"Rossing P, Filippatos G, Agarwal R, Anker SD, Pitt B, Ruilope LM, et al. Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy. Kidney Int Rep. 2022;7:36\u201345.","journal-title":"Kidney Int Rep"},{"key":"2175_CR47","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709\u201317.","journal-title":"N Engl J Med"},{"key":"2175_CR48","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","volume":"351","author":"DN Juurlink","year":"2004","unstructured":"Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med. 2004;351:543\u201351.","journal-title":"N Engl J Med"},{"key":"2175_CR49","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1001\/jamainternmed.2020.0193","volume":"180","author":"Y Qiao","year":"2020","unstructured":"Qiao Y, Shin JI, Chen TK, Inker LA, Coresh J, Alexander GC, et al. Association between renin-angiotensin system blockade discontinuation and all cause mortality among persons with low estimated glomerular filtration rate. JAMA Intern Med. 2020;180:718\u201326.","journal-title":"JAMA Intern Med"},{"key":"2175_CR50","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa2210639","volume":"387","author":"S Bhandari","year":"2022","unstructured":"Bhandari S, Mehta S, Khwaja A, Cleland JGF, Ives N, Brettell E, et al. for the STOP ACEi Trial Investigators. Renin-angiotensin system inhibition in advanced chronic kidney disease. N Engl J Med. 2022;387:2021\u201332.","journal-title":"N Engl J Med"},{"key":"2175_CR51","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1681\/ASN.2020050682","volume":"32","author":"E Fu","year":"2021","unstructured":"Fu E, Evans M, Clase C, Tomlinson LA, van Diepen M, Dekker FW, et al. Stopping renin-angiotensin system inhibitors in patients with advanced CKD and risk of advanced CKD and risk of adverse outcomes: A nationwide study. J Am Soc Nephrol. 2021;32:424\u201335.","journal-title":"J Am Soc Nephrol"},{"key":"2175_CR52","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD work group.","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD work group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105:S117\u2013314.","journal-title":"Kidney Int"},{"key":"2175_CR53","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.2015.7446","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris GL, Pitt B, Weir MR, Freeman M, Mayo MR, Garza D, et al. for the AMETHYST-DN Investigators. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease. The AMETHYST-DN randomized clinical trial. JAMA. 2015;314:151\u201361.","journal-title":"JAMA"},{"key":"2175_CR54","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","volume":"372","author":"MR Weir","year":"2015","unstructured":"Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, et al. for the OPAL-HK investigators. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015;372:211\u201321.","journal-title":"N Engl J Med"},{"key":"2175_CR55","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1001\/jama.2014.15688","volume":"312","author":"M Kosiborod","year":"2014","unstructured":"Kosiborod M, Rasmussen H, Lavin P, Qunibi WY, Spinowitz B, Packham D, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia. The HARMONIZE randomized clinical trial. JAMA. 2014;312:2223\u201333.","journal-title":"JAMA"},{"key":"2175_CR56","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1411487","volume":"372","author":"DK Packham","year":"2015","unstructured":"Packham DK, Rasmussen HS, Lavin PT, El-Shahawy MA, Roger SD, Block G, et al. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med. 2015;372:222\u201331.","journal-title":"N Engl J Med"},{"key":"2175_CR57","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391:109\u201321.","journal-title":"N Engl J Med."}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02175-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02175-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02175-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T22:02:52Z","timestamp":1749074572000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02175-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2175"],"URL":"https:\/\/doi.org\/10.1038\/s41440-025-02175-2","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"assertion":[{"value":"24 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}